BRITISH SOCIETY FOR HAEMATOLOGY

62nd Annual Scientific Meeting of the British Society for Haematology

 

3-5 April 2022 Manchester
Close
N. Poster
Poster title
Applicant name
Status
  PO-001 Oral azacitidine in patients with acute myeloid leukemia in first remission after intensive chemotherapy: long-term overall survival results from the phase 3 QUAZAR AML-001 trial Dale Owens Received Received
  EP-001 Next generation sequencing in myeloid neoplasms: the South East of Scotland Experience Christopher Mullen Received Received
  EP-002 Are Individuals of a Lower Socio-Economic Class Not Able to Receive Treatment for Acute Myeloid Leukemia due to Cost? A Prospective Analysis of 200 Patients in India. Sasmith Menakuru Received Received
  EP-003 The UK Real-world Experience of CPX-351 for the Treatment of Therapy-related Acute Myeloid Leukaemia and Acute Myeloid Leukaemia with Myelodysplasia-related Changes: CREST Retrospective Clinical Trial Design Priyanka Mehta Received Received
  PO-004 Performances of Targeted RNA Sequencing for the Analysis of Fusion, Mutation, Exon Skipping and Expression in Hematological Tumors Jing Li Received Received
  EP-004 Leukocytapheresis for hyperleukocytosis in acute myeloid leukaemia a survey of current practice Julia Wolf Received Received
  PO-005 Beyond the In-Practice CBC: The Research CBC Parameters-Driven Machine Learning Predictive Modeling for Early Differentiation among Leukemias Rana Zeeshan Haider Received Received
  EP-005 Blinatumomab and inotuzumab ozogamicin for acute lymphoblastic leukaemia: data from the South East Scotland Cancer Network Christopher Mullen Received Received
  PO-006 One size fits all: a fixed (not weight-adjusted) dose of prophylactic liposomal amphotericin B is not associated with a higher rate of breakthrough invasive fungal infections in patients with higher weight Sion Williams Received Received
  EP-006 Fever-to-needle time in the neutropenic cohort: are we meeting the gold-standard? Kritika Kalia Received Received
  EP-007 Single Center, Real-world Retrospective Analysis of the Use of Azacitadine and Venetoclax as First Line Treatment In Patients with Acute Myeloid Leukaemia During the COVID-19 Pandemic Sarah Ahmed Bassiony Received Received
  PO-007 Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Therapy-related Myeloid Neoplasms, Antecedent Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms Kathryn Moulton Received Received
  PO-008 CPX-351 Treatment for Acute Myeloid Leukaemia in England: Real-world Outcomes in Adults Aged 60 Years Alex Legg Received Received
  EP-008 A simple intervention improved compliance with the COVID-19 swabbing policy for patients receiving chemotherapy in the Royal Bolton Hospital haematology department Lowri Edwards Received Received
  EP-010 Analysis of Haematology Consult Cases to Design a Consult Request Pro Forma in a Tertiary University Teaching Hospital David Egong Received Received
  PO-011 Purified phospholipase A2 from Pseudechis australis snake venom a novel anticancer agent for the treatment of precursor-B acute lymphoblastic leukaemia. James Boncan Received Received
  PO-012 Management of non-severe aplastic anemia: laboratory workup and treatment patterns. Giulio Cassanello Received Received
  EP-012 Review of bone marrow aspiration and trephine biopsies; a single university hospital report Zahraa Al-Dulaimi Received Received
  EP-013 Review of local practice and experience: a survey regarding bone marrow biopsies in a UK tertiary centre Kiri Dixon Received Received
  PO-013 Reporting Language in Haematological Malignancies Sophie Ralston Received Received
  PO-014 Audit outcomes of the Referral Pathway for Haematology Patients to the Intensive Care Facility at the University Hospital of Wales During the COVID Pandemic Medhavi Ratnayake Received Received
  EP-014 Haematology SpR Patient Safety Lead: A valuable contribution to Clinical Governance Michelle Melly Received Received
  EP-015 Thrombocytopenia in COVID-19 patients on ECMO Can Jones Received Received
  PO-015 Choose your own story: combining interactive voting technology with high-fidelity patient simulation for undergraduate transfusion teaching Sophie Holmes Received Received
  EP-016 Dasatinib Related Pleural Effusions: Real-World Experience in a District General Hospital Wing Yee Chris Sin Received Received
  PO-016 Under or delayed transfusion: Risk factors leading to patient deaths. Shruthi Narayan Received Received
  PO-017 Reducing Unnecessary Blood Tests on a Haematology Ward at Salisbury NHS Foundation Trust Lee Grimes Received Received
  EP-017 Adherence to national guidelines for patients with very low B12 levels 15Ong/l Wayne Thomas Received Received
  PO-018 A multidisciplinary approach to improvement of a bone marrow biopsy service: advice from both service users and service providers Kiri Dixon Received Received
  EP-018 PERFORMANCE OF SOME HAEMATOLOGICAL MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE IN PREECLAMPSIA Theresa Nwagha Received Received
  PO-019 Home transfusions balancing safety with individualised care Shruthi Narayan Received Received
  EP-019 Prevalence and clinicopathological features of driver mutations in BCR-ABL1 negative classical myeloproliferative neoplasm- A single centre study from North India Khaliqur Rahman Received Received
  EP-020 IMMUNE THROMBOCYTOPENIA: BE ALWAYS AWARE Paula Melero Valentín Received Received
  PO-020 Endocrine Complications in Patients with Thalassemia: A Single Centre Experience Maab Ibrahim Received Received
  PO-021 The Haematology Taster Day Inspiring the next generation of haematologists Julia Wolf Received Received
  EP-021 Platelets Indices as Diagnostic Markers for Immune Thrombocytopenia and Surrogate Predictors for Prednisolones Response, Khartoum - Sudan Rabea Saeed Received Received
  PO-022 Strangers in a foreign land: Foundation year 1 doctors introduction and experiences in Haematology-Oncology Alessandra Lepori Received Received
  EP-022 Effect of Iron Deficiency Anemia on HbA1c levels in a cohort of patients with Type 2 diabetes mellitus(T2DM) in Sri Lanka. Chitranga Kariyawasan Received Received
  PO-023 Developing the role of the Haematology ward in undergraduate medical education with the creation of a novel clinical placement Richard Hinton Received Received
  EP-023 Usefulness of Ferritin and sTfR/(log)ferritin (sTfR-F) index in identifying iron deficiency anaemia among blood donors Theresa Nwagha Received Received
  EP-024 Reducing Platelet Wastage in a Regional Australian Haematology Centre: Impact of Phone Calls to Clinical Staff for Expiring Platelet Stock Emily Powley Received Received
  PO-024 Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies Cory Pfeiffenberger Received Received
  EP-025 Increasing incidence of Folate and Vitamin B12 deficiency in pregnant population and Risk Stratification of at risk women with early diagnosis and management Rakhee Saxena Received Received
  PO-025 Treatment free responses and long term outcomes in ITP patients with an optimal response to thrombopoietin receptor agonists Asad Charania Received Received
  EP-026 Evaluation of the hematological changes in the full blood count of regular apheresis platelet donors at National Blood Centre Narahenpita in Sri Lanka. Gauri Jayasinghe Received Received
  PO-026 Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib Gemma Shay-Lowell Received Received
  PO-027 Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis update of clinical and translational data from the ongoing MANIFEST trial Hannah Greetham Received Received
  EP-027 Assessment of the Relationship between ferritin levels and hematological ratios in Thalassemia Major Dorra Rhim Received Received
  PO-028 EMT transcription factor Zeb1 regulates T-cell differentiation from haematopoietic stem cells during ontogenesis Hamed Alzahrani Received Received
  EP-028 Adapting heparin monitoring in response to COVID-19 Emily Patrick Received Received
  EP-029 Impact Of National Hemovigilance Reporting System: A Report From Private Hospital Based Blood Centre In India. Bala Bhasker Received Received
  PO-029 Association of red blood cell distribution width and lactate dehydrogenase with disease transformation in essential thrombocythaemia and polycythaemia vera patients: a UK cohort study using electronic health records Lewis Carpenter Received Received
  EP-030 massive transfusion or massive confusion? Mariem Cheikhrouhou Received Received
  PO-031 Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib Ruben Mesa Received Received
  EP-031 Consequences of immune defects in patients with diffuse large B cell lymphoma (DLBCL). Katarina Flatman Received Received
  PO-032 Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Nave Myelofibrosis Patients Ruben Mesa Received Received
  EP-032 Relapsed/Refractory Hodgkins lymphoma: a real world analysis of salvage therapy in the East of England Patrick Sarkies Received Received
  EP-033 Venous thromboembolism in newly diagnosed lymphoma patients: A review of 102 patients in a district general hospital aiming to identify those at risk Aoife Dervin Received Received
  PO-033 Effects of cessation of venesection on serum ferritin level and liver function among older patients with haemochromatosis as a result of the Covid-19 pandemic. Omolade Dada Received Received
  PO-034 Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic Jaki Nave Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status Jean-Jacques Kiladjian Received Received
  EP-034 Osteoporotic fracture risk in Non-Hodgkins lymphoma patients over the age of 70 treated with glucocorticoid containing chemo-immunotherapy regimens; A retrospective audit at a District General Hospital Patrick Isola Received Received
  PO-035 Characterisation of Cardiovascular Risk in a Contemporary Cohort of Patients with Myeloproliferative Neoplasms Dipal Mehta Received Received
  EP-035 Experience of delivering MATRIX chemotherapy and autologous stem cell transplant for central nervous system lymphoma within South East Scotland Sarah Beverstock Received Received
  PO-036 Pegylated Interferon is an effective and well-tolerated cytroreductive agent in patients with myeloproliferative neoplasms aged over 60 years. Hannah Al-Yousuf Received Received
  EP-036 Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial Lay Ean Tan Received Received
  PO-037 Iron Status of Pregnant Women with Sickle Cell Disease (SCD) Edeghonghon Olayemi Received Received
  EP-037 Course features and the effect of various therapies on the treatment outcome of hepatitis C associated marginal zone lymphoma (HCVMLZ) Sergey Lepkov Received Received
  PO-038 Enhancing chronic myeloid leukaemia (CML) patient safety and treatment management - Development of a management and audit tool for patients on tyrosine kinase inhibitor (TKI) therapy. Toby Jones Received Received
  EP-038 Ibrutinib therapy related uveitis: A single-centre case series and literature review Anita J M Kalakonda Received Received
  EP-039 Management of Primary Testicular Lymphoma within South-East Scotland within the last 10 years Jennifer Clarke Received Received
  PO-039 Assessing the utility of peripheral blood monocyte analysis and the fraction of classical monocytes (CD14ve CD16-ve) in the diagnosis of Chronic Myelomonocytic Leukaemia. Jennifer Mills Received Received
  EP-040 A Retrospective Analysis of the Covid-19 Pandemic Effect on Lymphoma Presentations and Diagnostic Pathways at Salisbury NHS Foundation Trust Lee Grimes Received Received
  PO-040 Sickle screening of Blood Donors in Scotland using High Performance Liquid Chromatography. Are we opening Pandoras box? Nicole Priddee Received Received
  EP-041 Quality of Life Reported Outcomes in Published Research on Waldenstroms Macroglobulinaemia: A systematic literature review Sotirios Bristogiannis Received Received
  PO-042 An audit of compliance with BSH haemoglobinopathy patients transfusion requirements and antibody prevalence in UK tertiary centre hospital blood bank. Suzanne Makki Received Received
  EP-043 Impact of CD38 Gene Polymorphism (rs1800561) on Hematological Parameters and Clinical Staging in Patients with Chronic Lymphocytic Leukemia Sahar Elbager Received Received
  PO-043 Time to first plasma exchange in TTP - a regional Scottish experience Christopher Mullen Received Received
  EP-044 Results of the treatment of patients with local stages of Hodgkins lymphoma Evgeniya Paramonova Received Received
  PO-045 Assessment of intoxication indexes in local cold injury Gennadiy Kovalov Received Received
  PO-046 Improving compliance with blood and platelet transfusion thresholds on a tertiary haematology ward Jenny Jia Ling Cao Received Received
  EP-046 Outcomes of patients referred with lymphadenopathy to the haematology service in the London North West University Healthcare NHS Trust between January 2019 and March 2021 Clemency Britton Received Received
  EP-047 Comparing the Psychosocial Impacts of the COVID-19 Pandemic Between Haematological Cancer and Myeloma Patients: Findings From an Online Survey Stephen Quinn Received Received
  PO-047 HIV, Hepatitis B and C viruses and syphilis coinfection among blood donors inhospital settings. Supriya Kumari Received Received
  PO-048 Haematological changes & in-hospital mortality in severe COVID-19 Sergio Gama Received Received
  EP-048 Quality of life assessment in multiple myeloma is feasible, biologically meaningful and can suggest appropriate interventions. Luke Carter-Brzezinski Received Received
  PO-049 ABO-related D-dimer elevation and severity In SARS-cov2-infected Tunisian patients Amira Hourani Received Received
  EP-049 Real-world experience of thrombotic complications associated with immunomodulatory (IMID) therapy in newly diagnosed and relapsed patients with multiple myeloma (MM). Lowri Morgan Received Received
  EP-050 Carfilzomib-related thrombotic microangiopathy a single centre case series Muhammed Saleh Received Received
  PO-050 RDW: useful prognostic marker in acute COVID-19 infection Sergio Gama Received Received
  EP-051 Survival in multiple myeloma patients following autologous stem cell transplantation, a single centre retrospective case series between 2015 and 2020 Rufaida Osman Received Received
  EP-052 Clinical utility of investigating for immune deficiency disease and light chain myeloma at low globulin levels indra ramasamy Received Received
  EP-053 Pegcetacoplan Patient Compliance Rates In PEGASUS And PRINCE Phase 3 Trials Compared To Published Oral Medication Compliance Rates In Literature Michael Yeh Received Received
  PO-053 Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results Carmen Ramirez Received Received
  EP-054 The uptake of vaccinations in adults with sickle cell disease receiving care at the Cambridge University Hospitals NHS Foundation Trust Joanna Kucharczak Received Received
  EP-055 Right dose, right time and right communication: patient feedback on management of acute painful episodes of sickle cell disease Sophie Holmes Received Received
  PO-055 Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study Sukanya Chaudhury Received Received
  PO-056 Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study Sukanya Chaudhury Received Received
  EP-056 Thromboprophylaxis for Nursing home residents with COVID-19 a single centre approach Radha Shah Received Received
  PO-057 Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Jacqueline Webster Received Received
  EP-057 Pattern of Venous Thrombosis events in 2020 associated with COVID, in a large teaching hospital Huw Rowswell Received Received
  PO-058 Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study Will Cherry Received Received
  EP-058 ASSOCIATION OF MEAN PLATELET VOLUME / PLATELET COUNT RATIO WITH CLINICAL SEVERITY AND INFARCT VOLUME IN PATIENTS WITH ACUTE ISHEMIC STROKE Muhammad Wasi Nayyar Received Received
  PO-059 Real-World Experience of Rapid Obinutuzumab Administration: Time to Change Obinutuzumab Infusion Rates Joel Cunningham Received Received
  EP-059 A single centre retrospective review looking at antiphospholipid screens for those on DOACs including follow up testing and the subsequent clinical sequelae. Michelle Melly Received Received
  EP-060 Increased levels of factor VIII on admission, predict intensive care unit transferal and mortality in hospitalized COVID-19 patients. Mohamed El Horri Received Received
  PO-060 Outcomes and prognostic factors for adult patients with Post-Transplant Lymphoproliferative Disorders: the Thames Valley experience Maria Chiara Barbanti Received Received
  PO-061 The MCL Biobank Observational Study comes of age Sarah Mant Received Received
  EP-061 Collaborative anticoagulation counselling for recently discharged patients: From hospital to the community pharmacy Abigail Mezzullo Received Received
  EP-062 Subcutaneous unfractionated heparin in patients with end stage kidney disease requiring anticoagulation Giulia Simini Received Received
  PO-062 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress) Sukanya Chaudhury Received Received
  PO-063 Bisphosphonate prophylaxis in Lymphoma patients treated with steroid containing regimens Rashmi Chandrashekar Received Received
  EP-063 Improving venous thromboembolism risk assessment practice and prophylaxis prescription for the patients admitted to medical assessment unit Amar Ali Received Received
  EP-064 Case series of the first use of Andexanet Alfa at Salisbury NHS Foundation Trust Lee Grimes Received Received
  PO-064 Efficacy of Mogamulizumab in Mycosis Fungoides by Patient Blood Involvement and Time to Response Analysis in Mycosis Fungoides and Sézary Syndrome: a Post Hoc Analysis of the MAVORIC Study Lay Ean Tan Received Received
  EP-065 A retrospective review of the role of platelet aggregometry in the diagnosis of platelet disorders in a single Comprehensive care centre Benjamin Gray Received Received
  PO-065 Undiagnosed Lymphadenopathy Pathway Is a Haematology-led service warranted? Rachel Wright Received Received
  PO-066 Clinical Outcomes in Relapsed DLBCL Patients Approved for CAR-T Therapy; a Single Centre Study John Hall Received Received
  PO-067 Real-World Outcomes for Dexamethasone, Rituximab and Cyclophosphamide (DRC) in the Treatment of Waldenström Macroglobulinaemia: An Eight-Year Retrospective Review Ravindu De Silva Received Received
  EP-067 An audit of therapeutic anticoagulation with Anti-Xa monitoring during pregnancy Sajida Kazi Received Received
  PO-068 Identification of a Novel Proliferating Cell Fraction in Chronic Lymphocytic Leukaemia with High Expression of IgM and Chemokine Receptors Robbert Hoogeboom Received Received
  EP-068 ALLELE Study: A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV PTLD) after Failure of Rituximab Sridhar Chaganti Received Received
  PO-069 A novel cardio-oncology pathway for the detection of early toxicity in patients receiving anthracycline chemotherapy for lymphoma Clare Bannister Received Received
  EP-070 Is Posaconazole Therapeutic Drug Monitoring Required In Primary Prophylaxis Of Invasive Fungal Disease In Adult Allogeneic Stem Cell Recipients? David Quinn Received Received
  PO-070 BRUIN MCL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Nave Mantle Cell Lymphoma (Trial in Progress) Sukanya Chaudhury Received Received
  PO-071 CARTITUDE-2 Cohort B: Efficacy and Safety of Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T-Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients With Multiple Myeloma and Early Relapse After Initial Treatment Priyanka Nair Received Received
  EP-071 Reduced intensity conditioning with fludarabine,treosulfan and anti-thymocyte globulin (FluTreoATG) - A single centre experience Yadanar Lwin Received Received
  EP-072 Pregnancy outcomes following bone marrow transplant: findings of clinician survey and update on data linkage and UKOSS survey Katherine Birchenall Received Received
  PO-072 First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple Myeloma Jared Saunders Received Received
  EP-073 A real-world evidence systematic literature review of the metrics used to detect veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation Diane Lockard Received Received
  EP-074 The emerging advanced nurse practitioner role in haematology-does it cause confusion or provide support to the traditional clinical nurse specialist role? Roxanne Spencer Received Received
  EP-075 Nurse-led Telephone Clinics for Myeloproliferative Neoplasms (MPN): Developing service provision through COVID-19 Hayley Gleadhill Received Received
  PO-075 Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multipl Salgo Elenjikamalil Received Received
  EP-076 Role of IL6 in developing resistance of AML cells to standard chemotherapy Ahmed Elmarghany Received Received
  PO-076 The impact of a delayed diagnosis on myeloma patients quality of life Amy Capper Received Received
  PO-077 Treatment delivery and outcomes in elderly myeloma patients at The Royal Bournemouth hospital; Real life data Alistair Smith Received Received
  EP-077 Pattern of Haemolysis During Pregnancy in Women with Sickle Cell Disease (SCD), and its Effects on Feto-maternal Outcome Edeghonghon Olayemi Received Received
  EP-078 Real World Data on Efficacy of Pharmaceutical-grade L-glutamine in preventing Sickle Cell Disease-related acute complications and haemolysis in Pediatric and Adult patients. Mohamed Yassin Received Received
  PO-079 Haematology clinic presentation of benign plasma cell granuloma and lymphomatoid granulomatosis with intracranial involvement - a case series. Kanchana De Abrew Received Received
  EP-079 An Audit Of The Process Of Care In Surveillance Services For Children With Sickle Cell Disease In Wales Charlie Jeffkins Received Received
  EP-080 Prevalence of Bleeding Disorders in Nicaragua in the period 2004-2020. Sergio Luis Gustavo Aguilera Covarrubias Received Received
  EP-081 Beginning of the Hemophilic Arthropathy in children of 7 to 11 years old in Nicaragua in the absence of replacement treatment: Series of 9 cases. Sergio Luis Gustavo Aguilera Covarrubias Received Received
  PO-081 Outcomes of Patients (pts) with Previously Treated Multiple Myeloma (MM) from European Countries and the United Kingdom, Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) Versus Bortezomib and Dexamethasone (Vd): A Post-Hoc Analysis from the BOS Tamar Aprahamian Received Received
  PO-082 A META-ANALYSIS OF THE RATE OF MALIGNANT PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: PRELIMINARY FINDINGS FROM A SYSTEMATIC REVIEW Stephen Quinn Received Received
  PO-083 Are we looking for Monoclonal Gammopathy of Renal Significance (MGRS)? An audit of investigations in current clinical practice Lisa Jeffers Received Received
  PO-084 Quality of Life and Symptom Burden of Paroxysmal Nocturnal HaemogIobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe Shaneil Sonecha Received Received
  PO-085 Retrospective analysis of the burden of vasoocclusive events experienced by sickle cell disease (SCD) patients in the integrated health and social care system in North West London Amir Nawaz Received Received
  PO-086 The Pharmacokinetics, Pharmacodynamics, And Safety Of Intravenous Pegcetacoplan Administration In Healthy Subjects Michael Yeh Received Received
  PO-087 Association of CR1 and C3 polymorphisms with C3-mediated extravascular haemolysis in Paroxysmal Nocturnal Haemoglobinuria April Joy Baral Received Received
  PO-089 Real-World Experience of Patients With Sickle Cell Disease Treated With Voxelotor: A Multicenter, Retrospective Study Biree Andemariam Received Received
  PO-090 Pegcetacoplan Treatment In Patients With Paroxysmal Nocturnal Hemoglobinuria And Baseline Hemoglobin Levels At Or Above 10 g/dL Michael Yeh Received Received
  PO-091 Predictors for improvement in patient-reported outcomes: post-hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-nave patients with paroxysmal nocturnal hemoglobinuria (PNH) Colin Griffin Received Received
  PO-094 Breakthrough Hemolysis Rates Among Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switched From Eculizumab to Ravulizumab Treatment: A Real-World Analysis Michael Yeh Received Received
  PO-095 Management of autoimmune haemolytic anaemia during pregnancy or post-partum: a single centre experience. Marta Bortolotti Received Received
  PO-096 Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation From International PNH Registry Patient Data Colin Griffin Received Received
  PO-098 Mapping the Prothrombin Binding Site of Pseutarin C by Site-directed PEGylation Fatma Isik Ustok Received Received
  PO-099 Efficacy of thrombopoietin receptor agonists in Evans syndrome: an international multicenter experience Nicola Cecchi Received Received
  PO-101 Postdischarge complications and mortality of hospitalised patients with COVID-19 in East London Hospitals Aiman Entwistle Received Received
  PO-102 Drug-induced thrombotic thrombocytopenic purpura (TTP): review of European and North American pharmacovigilance report data Sara Hosseinzadeh Received Received
  PO-103 Safety and Efficacy of Apixaban as Thromboprophylaxis in Multiple Myeloma Patients Receiving Chemotherapy: a Prospective Cohort Study Zara Sayar Received Received
  PO-105 Platelet function abnormalities are common amongst women with menorrhagia referred for surgical intervention Alison Delaney Received Received
  PO-107 The advantages of using expansion microscopy to visualise single platelets and aggregates Raluca Alexandra Iulia Neagoe Received Received
  PO-108 Tranexamic Acid use to improve outcomes in Meningioma Surgery Abigail Clynch Received Received
  PO-109 Internal and external validation of venous thromboembolism predictive model in hematologic malignancies. Agnerys López Sacerio Received Received
  PO-110 Thromboembolism in COVID-19 patients on ECMO Can Jones Received Received
  PO-111 Vaccine Induced Immune Thrombocytopenia and Thrombosis Syndrome post second dose of ChAdOx1 nCov-19 vaccine: Case Presentation Amy Webster Received Received
  PO-113 The effect of lockdown and media coverage following vaccine rollout on Deep Vein Thrombosis (DVT) clinic activity during the first year of the COVID-19 pandemic a single-centre experience. George Bell Received Received
  PO-114 Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma Patrick Deifik Received Received
  PO-115 Excellent outcome with FB4 conditioning regimen in patients affected with myeloid malignancies older than 55 and with HCTI-score 2. A new insight for raising the upper limit for myeloablation in fit patients and high-risk diseases. Daniele Avenoso Received Received
  PO-116 Use of a foamy-virus vector system to produce an off-the-shelf anti-CD19 CAR T cell product Ioanna Lazana Received Received
  PO-118 The future of Outpatient Haematology : Self Supported Follow-up (SSFU) for patients with Chronic Lymphocytic Leukaemia (CLL) and Monoclonal Gammopathy of Undetermined Significance (MGUS) - An online Portal audit. Ruth Jackson Received Received
  PO-121 Just one thing what would myeloma patients change about their treatment and care? Jess Turner Received Received
  PO-122 Disease Knowledge in Adolescents and Young Adults with Sickle Cell Disease in a Low Resource Setting. Bonaventure Ikediashi Received Received
  PO-123 What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis? Nick Fordham Received Received
  PO-124 Aberrant expression of lncRNA leukemia-induced non-coding activator RNA predicts poor Outcome in Childhood T-Acute Lymphoblastic Leukemia Nashwa El-Khazragy Received Received
  PO-125 National protocol required for consistent transfusion duration in patients having regular tranfusion ? Resulrs from a national survey and recommendations Eleni Louka Received Received
  PO-126 Need to contextualize the fight against sickle cell disease in regions with limited resources: the case of the Democratic Republic of the Congo Abdala Aimé Received Received
  PO-127 APPRAISAL OF QUALITY OF LIFE AND ASSESMENT OF FACTORS INFLENCING QUALITY OF LIFE IN TRANSFUSION DEPENDENT BETA THALESEMMIA - A CROSS SECTIONAL STUDY Srividhya Senthil Received Received
  PO-128 Individualized prophylaxis with personalized target trough FVIII level optimized clinical outcomes in boys with severe hemophilia A Kun Huang Received Received
  PO-129 Thrombopoietin receptor agonists for treatment of new and relapsed immune thrombocytopenia in children- a single centre experience Eman Hassan Received Received
  PO-130 DVT prophylaxis in sixteen and seventeen-year-olds and the NICE guidelines should adult risk assessment tools be used for children? Jan Muhammad Received Received
  PO-131 A year of coagulation studies in a Paediatric Emergency Department: A service evaluation project John Wilson Received Received
  PO-132 Positive Impact of Covid-19 on Providing Health Care Services: Experience from a Large Haemophilia Comprehensive Care Centre Emma Whiting Received Received
  PO-133 Single Centre Study on Safety and Efficacy of Rivaroxaban in Paediatric Venous Thromboembolism Eman Hassan Received Received
  PO-134 Impact of levofloxacin-based prophylaxis during the pre-engraftment phase in allogeneic hematopoietic stem cell transplant pediatric recipients: a single-center retrospective matched analysis. Martina DAgostin Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
20:05
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

62nd Annual Scientific Meeting of the British Society for Haematology

 

3-5 April 2022 Manchester
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 03/04/2022 TO 03/04/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert